Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario Virgen del Rocío (12)

2023

  1. Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients

    Medicina (Kaunas, Lithuania), Vol. 59, Núm. 8

2020

  1. Comparative study between two european inception cohorts of patients with early systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 38, Núm. 5, pp. 925-932

2019

  1. Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics

    Translational Psychiatry, Vol. 9, Núm. 1

2018

  1. Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort

    Lupus, Vol. 27, Núm. 14, pp. 2253-2261

2017

  1. Características clínicas al diagnóstico de una cohorte prospectiva de pacientes con lupus eritematoso sistémico atendidos en servicios de Medicina Interna españoles: estudio RELES

    Revista Clinica Espanola, Vol. 217, Núm. 1, pp. 7-14

2016

  1. First month prednisone dose predicts prednisone burden during the following 11 months: An observational study from the RELES cohort

    Lupus Science and Medicine, Vol. 3, Núm. 1

  2. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies

    Seminars in Arthritis and Rheumatism, Vol. 45, Núm. 4, pp. 391-399

  3. Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 34, Núm. 3, pp. 466-472

2012

  1. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts

    Autoimmunity Reviews, Vol. 11, Núm. 5, pp. 357-364

  2. Neurological soft signs in patients with psychosis and cannabis abuse: a systematic review and meta-analysis of paradox.

    Current pharmaceutical design, Vol. 18, Núm. 32, pp. 5156-5164

2011

  1. Biologics use in SLE in 23 Centers - Data from the International Registry for Biologics In SLE (IRBIS)

    ARTHRITIS AND RHEUMATISM

2010

  1. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases

    Clinical and Experimental Rheumatology, Vol. 28, Núm. 4, pp. 468-476